Thrombolysis of rabbit's pulmonary embolism with thrombus-targeted urokinase immune liposome
10.3760/cma.j.issn.0253-3758.2009.11.022
- VernacularTitle:尿激酶免疫脂质体靶向溶栓治疗兔肺动脉血栓栓塞
- Author:
Cui-Ping LU
1
;
Hui YANG
;
Jue WANG
;
Xiao-Li DONG
Author Information
1. 华北煤炭医学院
- Keywords:
Pulmonary embolism;
Thrombolytic therapy;
Urinary plasminogen activator;
Liposomes
- From:
Chinese Journal of Cardiology
2009;37(11):1035-1038
- CountryChina
- Language:Chinese
-
Abstract:
Objective To develop thrombus-targeted urokinase immune iiposome through incorporating D-dimer monoclonal antibody (DDmAb) to liposome and observe the thrombolytic efficiency in a rabbit pulmonary thromboembolism (PE) model. Methods Reverse-phase evaporation method was used to develop targeted urokinase immune liposome by coupling DDmAb to urokinase liposome (liposomal-encapsalated urokinase) with glutaraldehyde. The PE models were induced by injecting 4 autologous emboli (2 mm×5 mm) through jugular vein catheter into pulmonary arteries. New Zealand white rabbits (n=32) were randomized into four groups: A group (TBS), B group (150 000 IU/kg UK), C group (30 000 IU/kg urokinase liposome) and D group (30 000 IU/kg urokinase immune liposome). The right ventricular pressure and the emboli size in pulmonary arteries were determined. Results The right ventricular pressure increased significantly in PE rabbits (P<0.01), the average value is (6.75±6.82)mm Hg(1 mm Hg= 0.133 kPa). Eighty minutes post various treatments, right ventricular pressure remained unchanged as post PE in group A [(40.15±11.22) mm Hg vs. (41.67±14.23) mm Hg], decreased to baseline level in group BandD [(34.71±8.67)mm Hg vs. (33.98±9.32)mm Hg, (30.65±6.67)mm Hg vs. (30.77± 6.85)mm Hg, all P>0.05], decreased but not returned to normal value in group C. Residual emboli size remained unchanged in group A and partly reduced in group C and more significantly reduced in group B and D. Hemorrhage of heart, kidney and liver was evidenced in group A but not in other groups. Conclusion Acute PE could be successfully treated by the thrombus-targeted ttrokinase immune liposome with D-dimer monoclonal antibody.
